All product and company names are trademarks^™ or registered^® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

*Breakthrough therapy designation granted for cholangiocarcinoma.

Reference: 6 Elevar Therapeutics. Press release. Accessed April 2, 2026. elevartx.com/2023/08/03/elevar-therapeutics-to-host-august-10-virtual-kol-event-on-phase-3-study-of-rivoceranib-in-combination-with-camrelizumab-in-unresectable-hepatocellular-carcinoma-uhcc/